<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588091</url>
  </required_header>
  <id_info>
    <org_study_id>HR-BLTN-III-NeoBC</org_study_id>
    <nct_id>NCT03588091</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer</brief_title>
  <official_title>A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Docetaxel Compared With Placebo Plus Trastuzumab and Docetaxel in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy
      and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel versus placebo and
      trastuzumab plus docetaxel given as neoadjuvant treatment in HER2 positive early stage or
      locally advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by independent review committee(IRC)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by sites</measure>
    <time_frame>Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4,each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival(EFS)</measure>
    <time_frame>Following surgery until Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Following surgery until Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance Disease-free Survival (DDFS)</measure>
    <time_frame>Following surgery until Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) during neoadjuvant period</measure>
    <time_frame>Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyrotinib Plus trastuzumab and docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo plus trastuzumab and docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>pyrotinib: 400mg orally daily;</description>
    <arm_group_label>arm1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo: 400mg orally daily;</description>
    <arm_group_label>arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;</description>
    <arm_group_label>arm1</arm_group_label>
    <arm_group_label>arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles</description>
    <arm_group_label>arm1</arm_group_label>
    <arm_group_label>arm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients, 18 years ≤ age ≤ 75 years；

          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Histologically confirmed invasive breast cancer（early stage or locally
             advanced）:Primary tumour greater than 2 cm diameter

          -  HER2 positive (HER2+++ by IHC or FISH+)

          -  Known hormone receptor status.

          -  Cardiovascular:Baseline left ventricular ejection fraction (LVEF)≥55% measured by ECHO

          -  Signed informed consent form (ICF)

        Exclusion Criteria:

          -  metastatic disease (Stage IV) or inflammatory breast cancer

          -  Previous or current history of malignant neoplasms, except for curatively
             treated:Basal and squamous cell carcinoma of the skin,Carcinoma in situ of the cervix.

          -  clinically relevant cardiovascular disease:Known history of uncontrolled or
             symptomatic angina, clinically significant arrhythmias, congestive heart failure,
             transmural myocardial infarction, uncontrolled hypertension ≥180/110);

          -  Unable or unwilling to swallow tablets.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong Wu, Dr.</last_name>
      <phone>+86-13601637369</phone>
      <email>wujiong1122@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

